Docoh
Loading...

DNLI Denali Therapeutics

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Company profile

DNLI stock data

(
)

Calendar

5 May 21
9 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 436.82M 436.82M 436.82M 436.82M 436.82M 436.82M
Cash burn (monthly) 23.94M (positive/no burn) 23.74M (positive/no burn) 16.75M (positive/no burn)
Cash used (since last report) 30.47M n/a 30.21M n/a 21.31M n/a
Cash remaining 406.35M n/a 406.61M n/a 415.51M n/a
Runway (months of cash) 17.0 n/a 17.1 n/a 24.8 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 May 21 Schuth Alexander O. Common Stock Sell Dispose S Yes Yes 57.39 445 25.54K 511,582
4 May 21 Schuth Alexander O. Common Stock Sell Dispose S Yes Yes 55.915 3,557 198.89K 512,027
4 May 21 Schuth Alexander O. Common Stock Sell Dispose S Yes Yes 55.091 5,998 330.44K 515,584
3 May 21 Watts Ryan J. Common Stock Sell Dispose S Yes Yes 59.917 851 50.99K 2,229,075
3 May 21 Watts Ryan J. Common Stock Sell Dispose S Yes Yes 59.119 3,485 206.03K 2,229,926
3 May 21 Watts Ryan J. Common Stock Sell Dispose S Yes Yes 58.447 13,997 818.08K 2,233,411
3 May 21 Tessier-Lavigne Marc Common Stock Sell Dispose S No Yes 61.2 98 6K 2,589,059
3 May 21 Tessier-Lavigne Marc Common Stock Sell Dispose S No Yes 60.08 3,139 188.59K 2,589,157
28 Apr 21 Sato Vicki L Common Stock Sell Dispose S No Yes 63.034 688 43.37K 135,755
28 Apr 21 Sato Vicki L Common Stock Sell Dispose S No Yes 62.047 597 37.04K 136,443

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

94.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 205 167 +22.8%
Opened positions 64 43 +48.8%
Closed positions 26 18 +44.4%
Increased positions 62 54 +14.8%
Reduced positions 64 45 +42.2%
13F shares
Current Prev Q Change
Total value 8.57B 2.93B +192.7%
Total shares 114.19M 81.69M +39.8%
Total puts 68.3K 69.9K -2.3%
Total calls 346.9K 52.1K +565.8%
Total put/call ratio 0.2 1.3 -85.3%
Largest owners
Shares Value Change
Crestline Management 19.46M $339.04M +59.5%
Douglas K Bratton 12.2M $1.02B NEW
Baillie Gifford & Co 12.19M $1.02B +12.6%
ARCH Venture Fund VIII 10.67M $893.61M NEW
Vanguard 7.93M $663.8M +18.3%
TROW T. Rowe Price 6.46M $541.49M +48.2%
BLK Blackrock 6.38M $534.06M +4.8%
Temasek 4.41M $369.42M 0.0%
FMR 3.51M $294.35M -27.9%
Gilder Gagnon Howe & Co 3.22M $269.69M -2.9%
Largest transactions
Shares Bought/sold Change
Douglas K Bratton 12.2M +12.2M NEW
ARCH Venture Fund VIII 10.67M +10.67M NEW
Crestline Management 19.46M +7.26M +59.5%
Flagship Pioneering 2.73M -3.25M -54.3%
Flagship Ventures Fund V 2.73M +2.73M NEW
TROW T. Rowe Price 6.46M +2.1M +48.2%
Baillie Gifford & Co 12.19M +1.36M +12.6%
FMR 3.51M -1.36M -27.9%
CS Credit Suisse 1.4M +1.32M +1626.2%
Vanguard 7.93M +1.22M +18.3%

Financial report summary

?
Competition
BiogenAstrazenecaRocheShireCytokineticsSanofiAbbvieProthenaMallinckrodtRegenxbio
Risks
  • Risks Related to Our Business, Financial Condition and Capital Requirements
  • A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or the perception of its effects, may materially and adversely affect our business, operations and financial condition.
  • Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
  • Risks Related to Regulatory Approval and Other Legal Compliance Matters
  • Our business is subject to complex and evolving U.S. and foreign laws and regulations, information security policies and contractual obligations relating to privacy and data protection, including the use, processing, and cross-border transfer of personal information. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.
  • Risks Related to Our Reliance on Third Parties
  • We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.
  • We currently contract with third parties for the manufacture of materials for our research programs, preclinical studies and clinical trials and expect to continue to do so for commercialization of some or all product candidates that we may develop. This reliance on third parties may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.
  • We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.
  • If we are unable to obtain and maintain patent protection for any product candidates we develop or for our BBB platform technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.
  • If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.
  • Our rights to develop and commercialize our BBB platform technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others or licenses granted by us to others.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
  • We may not be able to protect our intellectual property and proprietary rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • Issued patents covering our BBB platform technology, product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.
  • If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.
  • We may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, necessary rights to our BBB platform technology, product candidates or other technologies.
  • We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
  • Third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our BBB platform technology, product candidates and other technologies.
  • We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats.
  • We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.
  • We have engaged in and may in the future engage in acquisitions or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our business is subject to economic, political, regulatory and other risks associated with international operations.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
  • The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors.
  • If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock and trading volume could decline.
  • Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to decline significantly, even if our business is doing well.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.
  • If we are unable to maintain effective internal controls, our business, financial position and results of operations and growth prospects could be adversely affected.
  • We have not paid and do not expect to pay any dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock. Investors may never obtain a return on their investment.
  • Delaware law and provisions in our charter documents might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.
  • Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Management Discussion
  • *     Percentage is not meaningful.
  • Collaboration revenue. Collaboration revenue was $7.9 million and $3.6 million for the three months ended March 31, 2021 and 2020, respectively. The increase in collaboration revenue of $4.3 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020 was due to an increase in revenue from our collaboration with Takeda of $4.0 million driven by increased costs incurred in the underlying partnered programs, and revenue of $0.9 million from our collaboration with Biogen, partially offset by a decrease of $0.6 million in revenue from our collaboration with Sanofi driven by the termination of revenue for retained activities which have been transferred to Sanofi.
  • Research and development expenses. Research and development expenses were $60.2 million and $51.0 million for the three months ended March 31, 2021 and 2020, respectively.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accrual, cerebrospinal, CLE, cohort, CPRA, deferred, depressing, endpoint, ERT, estate, EU, Fast, GAG, Gaucher, GLP, glycosaminoglycan, IIIB, JDC, Kingdom, leukodystrophy, metachromatic, MLD, overview, passionately, payout, Pompe, proof, real, reclassified, RSU, therapy, Virtual, window
Removed: Aggregated, Biotechnologische, clarification, Codification, composition, constant, dated, ESPP, Fcab, Fighting, formally, HSR, investor, July, licensee, LLC, lysosomal, NASDAQ, Opioid, President, reconciliation, retrospective, sequester, traded, Trump, undisclosed, weighted, winding